Keros Therapeutics, Inc. - Common Stock (KROS)

CUSIP: 492327101

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class
Equity / Common Stock
Shares outstanding
30,507,667
Total 13F shares
10,926,163
Share change
+10,926,163
Total reported value
$409,790,602
Price per share
$37.51
Number of holders
51
Value change
+$409,790,602
Number of buys
51

Sponsored

Quarterly Holders Quick Answers

What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) as of Q2 2020

As of 30 Jun 2020, Keros Therapeutics, Inc. - Common Stock (KROS) was held by 51 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 10,926,163 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Foresite Capital Management IV, LLC, FMR LLC, VR Adviser, LLC, BlackRock Inc., CHI Advisors LLC, Logos Global Management LP, VANGUARD GROUP INC, and Invesco Ltd.. This page lists 51 institutional shareholders reporting positions in this security for the Q2 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2020 vs Q3 2025 Across Filers

Q3 2025 holders
151
Q2 2020 holders
51
Holder diff
-100
Investor Q3 2025 Shares Q2 2020 Shares Share Diff Share Chg % Q3 2025 Value $ Q2 2020 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.